|1.||Matsui, Takanori: 32 articles (04/2015 - 05/2005)|
|2.||Yamagishi, Sho-ichi: 31 articles (04/2015 - 08/2002)|
|3.||Imaizumi, Tsutomu: 25 articles (11/2012 - 04/2004)|
|4.||Nakamura, Kazuo: 24 articles (08/2010 - 08/2004)|
|5.||Yamagishi, Sho-Ichi: 18 articles (03/2015 - 04/2004)|
|6.||Takeuchi, Masayoshi: 14 articles (11/2012 - 08/2002)|
|7.||Yamagishi, S: 12 articles (01/2011 - 01/2002)|
|8.||Dass, Crispin R: 11 articles (11/2014 - 07/2006)|
|9.||Yoshida, Yumiko: 11 articles (03/2011 - 07/2006)|
|10.||Crawford, Susan E: 10 articles (12/2013 - 03/2003)|
09/01/2008 - "Pigment epithelium-derived factor (PEDF) ameliorates advanced glycation end product (AGE)-induced hepatic insulin resistance in vitro by suppressing Rac-1 activation."
09/01/2013 - "Further studies are needed to understand the mechanism of low HDL and raised pigment epithelium-derived factor and to determine if they are causally related to the pathobiology of insulin resistance."
10/01/2010 - "We aimed to study circulating pigment epithelium-derived factor (PEDF) in vivo in association with insulin resistance and in vitro in human adipocytes. "
03/01/2014 - "Pigment epithelium-derived factor (PEDF) plays an important role in insulin resistance (IR). "
09/01/2013 - "Serum pigment epithelium-derived factor is positively associated with homeostasis model assessment-insulin resistance and negatively associated with HDL. "
|2.||Osteosarcoma (Osteogenic Sarcoma)
11/01/2014 - "Pigment epithelium-derived factor (PEDF) has proven anti-osteosarcoma activity. "
01/01/2012 - "The potent antiangiogenic pigment epithelium-derived factor (PEDF) has shown promise against osteosarcoma, a tumour that originates in the bone and metastasises to the lungs. "
01/01/2007 - "In this study, we report the multimodal activity of pigment epithelium-derived factor (PEDF) in inhibiting osteosarcoma growth, angiogenesis and metastasis. "
07/01/2007 - "Pigment epithelium-derived factor overexpression inhibits orthotopic osteosarcoma growth, angiogenesis and metastasis."
01/01/2007 - "Inhibition of orthotopic osteosarcoma growth and metastasis by multitargeted antitumor activities of pigment epithelium-derived factor."
|3.||Lewis Lung Carcinoma
09/01/2012 - "In this study, we evaluated the potential of bone marrow-derived mesenchymal stem cells, genetically modified to express pigment epithelium-derived factor (PEDF) for the treatment of Lewis lung carcinoma (LLC). "
04/01/2012 - "AAV-mediated gene transfer of human pigment epithelium-derived factor inhibits Lewis lung carcinoma growth in mice."
06/01/2014 - "Enhanced efficacy of combination therapy with adeno‑associated virus-delivered pigment epithelium-derived factor and cisplatin in a mouse model of Lewis lung carcinoma."
10/01/2003 - "To determine whether intraocular gene transfer of pigment epithelium-derived factor (PEDF) protects the retina from ischemia-reperfusion injury. "
04/01/2013 - "In this conceptual study, we investigated the protective effects of pigment epithelium-derived factor (PEDF) and compared them with the properties of epidermal growth factor (EGF) in a rat model of ischemia-reperfusion injury. "
|5.||Diabetic Nephropathies (Diabetic Nephropathy)
01/01/2015 - "Our recent publication showed that a small bioactive pigment epithelium derived factor (PEDF) peptide (P78-PEDF) prevents the development of diabetic nephropathy (DN). "
11/01/2014 - "Elevated circulating pigment epithelium-derived factor predicts the progression of diabetic nephropathy in patients with type 2 diabetes."
08/01/2013 - "To further elucidate the mechanism of the anti-fibrogenic role of pigment epithelium-derived factor (PEDF) on diabetic nephropathy. "
01/01/2010 - "Urinary pigment epithelium-derived factor as a marker of diabetic nephropathy."
05/01/2008 - "Anti-inflammatory effects of pigment epithelium-derived factor in diabetic nephropathy."
|1.||Epidermal Growth Factor (EGF)
|5.||glucuronyl glucosamine glycan sulfate (Vessel)
|8.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|9.||Proteins (Proteins, Gene)
|10.||Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)
|2.||Heterologous Transplantation (Xenotransplantation)
|3.||Photochemotherapy (Photodynamic Therapy)
|5.||Drug Therapy (Chemotherapy)